Repligen (RGEN) Competitors

Biogen (NASDAQ:BIIB) and Repligen (NASDAQ:RGEN) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, media sentiment, earnings, institutional ownership, profitability, community ranking, valuation, dividends and risk.

Which has higher earnings and valuation, BIIB or RGEN?

Biogen has higher revenue and earnings than Repligen. Repligen is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biogen	$9.68B	2.07	$1.63B	$11.19	12.25
Repligen	$638.76M	14.27	$35.60M	-$0.37	-439.64

Does the media favor BIIB or RGEN?

In the previous week, Biogen had 30 more articles in the media than Repligen. MarketBeat recorded 58 mentions for Biogen and 28 mentions for Repligen. Repligen's average media sentiment score of 1.33 beat Biogen's score of 0.20 indicating that Repligen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Biogen	19 Very Positive mention(s)	6 Positive mention(s)	10 Neutral mention(s)	6 Negative mention(s)	1 Very Negative mention(s)	Neutral
Repligen	14 Very Positive mention(s)	3 Positive mention(s)	9 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Is BIIB or RGEN more profitable?

Biogen has a net margin of 16.87% compared to Repligen's net margin of -3.36%. Biogen's return on equity of 14.98% beat Repligen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biogen	16.87%	14.98%	8.76%
Repligen	-3.36%	3.90%	2.72%

Do analysts recommend BIIB or RGEN?

Biogen presently has a consensus price target of $211.85, suggesting a potential upside of 54.55%. Repligen has a consensus price target of $182.91, suggesting a potential upside of 12.44%. Given Biogen's higher probable upside, equities research analysts plainly believe Biogen is more favorable than Repligen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biogen	0 Sell rating(s)	17 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.43
Repligen	0 Sell rating(s)	5 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.64

Does the MarketBeat Community believe in BIIB or RGEN?

Biogen received 1405 more outperform votes than Repligen when rated by MarketBeat users. Likewise, 71.55% of users gave Biogen an outperform vote while only 67.60% of users gave Repligen an outperform vote.

Company	Underperform	Outperform
Biogen	Outperform Votes 1816 71.55%	Underperform Votes 722 28.45%
Repligen	Outperform Votes 411 67.60%	Underperform Votes 197 32.40%

Do institutionals & insiders believe in BIIB or RGEN?

87.9% of Biogen shares are held by institutional investors. Comparatively, 97.6% of Repligen shares are held by institutional investors. 0.2% of Biogen shares are held by insiders. Comparatively, 1.2% of Repligen shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Which has more volatility and risk, BIIB or RGEN?

Biogen has a beta of -0.08, suggesting that its stock price is 108% less volatile than the S&P 500. Comparatively, Repligen has a beta of 0.99, suggesting that its stock price is 1% less volatile than the S&P 500.

Summary

Biogen beats Repligen on 12 of the 18 factors compared between the two stocks.